Corporate | 17 January 2022 14:08

Achiko AG Announces Feature Article on How We Get Back to Normal with its AptameXTM Covid-19 Rapid Test Technology

EQS-News: Achiko AG / Key word(s): Miscellaneous
17.01.2022 / 14:08

Achiko AG Announces Feature Article on How We Get Back to Normal with its AptameX ^TM Covid-19 Rapid Test Technology

Zurich, 17 January 2022 – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) is pleased to announce a feature article in The Jakarta Post: “ How we get back to normal: Restoring Trust and Confidence through Testing with AptameX” which discusses how Achiko is contributing to provide affordable and accurate testing to Indonesia with its Covid-19 saliva-based rapid test AptameX (TM), which fills the gap between rapid tests and PCR testing.

The article is available at this link: https://www.thejakartapost.com/adv-longform/2022/01/17/how-we-get-back-to-normal-restoring-trust-and-confidence-through-testing-with-aptamex.html and within the News section of Achiko’s web site: https://www.achiko.com/news .

ABOUT ACHIKO AG
Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com ) is developing disruptive diagnostic solutions that puts people first. The company’s lead product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and an application for CE Mark approval in Europe will be submitted in 2022.

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX ^TM and companion health apps via its digital mobile health technology division, Teman Sehat ^TM . The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Headquartered in Zurich, Achiko has offices in Hong Kong, Jakarta, Seoul and Singapore.

Media contacts:

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

U.S. & Global
Jeanene Timberlake
RooneyPartners
E: jtimberlake@rooneypartners.com
T: +1 646 770 8858

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties, and other factors, which could cause the actual results, financial condition, performance, or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

End of Media Release

Language:	English
Company:	Achiko AG
	Tessinerplatz 7
	8002 Zurich
	Switzerland
E-mail:	ir@achiko.com
Internet:	https://www.achiko.com/
ISIN:	CH0522213468
Valor:	48788430
Listed:	SIX Swiss Exchange
EQS News ID:	1269554

End of News EQS News Service